A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations
| ISRCTN | ISRCTN43344383 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN43344383 |
| Protocol serial number | LK/FIL |
| Sponsor | Pall Biomedical Ltd (UK) |
| Funder | Pall Biomedical Ltd (UK) |
- Submission date
- 19/08/2002
- Registration date
- 19/08/2002
- Last edited
- 11/01/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr - -
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Leukaemia (acute), Leukaemia (chronic) |
| Intervention | 1. Arm A: Patients receive standard non-filtered, non-leukocyte-depleted blood products 2. Arm B: Patients receive Pall filtered blood or platelet donations |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Leukocyte-Depleted Red Cell and Platelet Donations |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 01/04/1992 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Key inclusion criteria | 1. Patients with acute leukaemia, chronic myeloid leukaemia, severe aplastic anaemia or high grade lymphoma 2. Patients already known to have Human Leukocyte Antigens (HLA) antibodies or recurrent febrile transfusion reactions are ineligible 3. Any age 4. Fit to undergo the treatments as defined in protocol |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/01/1990 |
| Date of final enrolment | 01/04/1992 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
11/01/2019: No publications found. All search options exhausted.
